研究作者建议，根据INTERLACE协议进行的诱导化疗应被纳入临床指南，作为改善局部晚期宫颈癌患者预后的选项。这种方法可以被纳入未来免疫疗法或其他靶向药物一线治疗的临床试验设计中。 参考文献：[1]McCormack, Mary et al. “Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.” Lancet (London, England) vol. 404,10462 (2024): 1525-1535. doi:10.1016/S0140-6736(24)01438-7
